John Vierling
Gastroenterology · Houston, TXNPI 1043390388
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Gilead at 41.8% of the total. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $1761.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$113K
- AstraZeneca$27K
- Ipsen Biopharmaceuticals, Inc$25K
- Mallinckrodt Hospital Products Inc.$24K
- Mallinckrodt Enterprises LLC$24K
- GSK$18K
- plus $39K from 12 others
Across 438 payments — averaging $5798.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$831K
- Gilead$406K
- Novartis$320K
- AbbVie$310K
- E.r. Squibb & Sons, L.L.C.$270K
- Pfizer$150K
- plus $253K from 7 others
What the payments were for
- Consulting fees$149,42755%
- Speaking & faculty fees$95,22535%
- Travel & lodging$21,1188%
- Food & beverage$3,7381%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 64 | $112,670 |
| AstraZeneca | 10 | $26,536 |
| Ipsen Biopharmaceuticals, Inc | 10 | $25,209 |
| Mallinckrodt Hospital Products Inc. | 8 | $24,359 |
| Mallinckrodt Enterprises LLC | 18 | $23,839 |
| GSK | 16 | $17,761 |
| Intercept Pharmaceuticals, Inc. | 12 | $14,163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $9,996 |
| Ipsen Innovation | 1 | $3,735 |
| Orphalan Inc | 2 | $3,172 |
| Merck | 2 | $3,114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $2,500 |
| Amgen | 1 | $1,950 |
| Pfizer | 1 | $162 |
| Eli Lilly | 1 | $155 |
| Fujifilm Wako Diagnostics U.S.A. Corporation | 1 | $126 |
| Perspectum Diagnostics Ltd | 1 | $45 |
| AbbVie | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$269,523 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- George TriadafilopoulosHouston$192K
- Chukwuma EgwimHouston$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.